Leerink Partners analyst Andrew Berens has maintained their bullish stance on AURA stock, giving a Buy rating on May 19.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Andrew Berens has given his Buy rating due to a combination of factors that highlight Aura Biosciences Inc’s strategic positioning in the market. The recent Oncologic Drugs Advisory Committee (ODAC) meeting discussed the NDA for Urogen’s UGN-102, which faced a split vote, indicating potential regulatory hurdles for UGN-102. This situation could delay a competitor for Aura’s bladder cancer program, potentially benefiting Aura by reducing immediate competitive pressures.
Moreover, the ODAC’s preference for randomized control trials (RCTs) for future approvals in intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) aligns with Aura’s potential regulatory strategy. Although Aura has not explicitly outlined its strategy, the challenges faced by Urogen suggest that Aura could gain a competitive edge by adhering to a more robust trial design. This strategic advantage, coupled with the potential delay of UGN-102, supports Berens’s optimistic outlook on Aura’s stock.
In another report released on May 19, Citizens JMP also reiterated a Buy rating on the stock with a $19.00 price target.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is neutral on the stock.